Relief Therapeutics Reports Final Data from the Study of RLF-TD011 for Treating Epidermolysis Bullosa
Shots:
- Relief reported final data from the investigator-initiated PoC study assessing the impact of RLF-TD011 (a stabilized hypochlorous acid solution) on microbiome diversity in chronic and acute wounds, focusing on severe EB types (junctional and dystrophic)
- The study achieved its 1EP, with RLF-TD011 reducing S. aureus by 24% after 8wks., which is correlated (rho=0.64) with wound size reduction and overall, 78% of treated wounds closed during this duration
- Microbiome analysis showed an increase in alpha diversity and beneficial bacteria, effectively reducing S. aureus, without harming helpful microbes. The improvement sustained for 4wks. after treatment, indicating a durable effect without regression or exacerbation
Ref: Relief Therapeutics | Image: Relief Therapeutics
Related News:- Relief Therapeutics and Eton Pharmaceuticals Join Forces to Commercialize Golike Products for Phenylketonuria
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
